Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saizen in Children with Idiopathic Short Stature
NCT01746862Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Dec 2012
- Primary completion
- Aug 2014
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatropin in Idiopathic Short Stature (ISS) (2 arms), sponsored by Merck KGaA. Primary endpoint: Change From Baseline in Height Velocity at Month 6. Started Dec 2012; status: completed.
02
Drugs
somatropin
03
Conditions
Idiopathic Short Stature (ISS)
Beyond the preview
Go deeper on NCT01746862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01746862.